Q-omics provides the consensus-scored FAM99B profile across patient tissues and cancer cell-line models. FAM99B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM99B is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, FAM99B RNA expression shows 6,380 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LIHC, and STAD as cancer lineages where FAM99B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM99B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM99B survival associations across molecular data types. FAM99B RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM99B RNA expression–survival associations across cancer types. High FAM99B expression shows unfavorable associations in TGCT, COAD, MESO and CHOL, but favorable associations in KIRC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM99B RNA expression.
This table summarizes FAM99B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM99B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM99B shows lower tumor expression in LIHC and CHOL. The LIHC box plot shows higher FAM99B RNA expression in normal versus tumor tissue (log2 FC = −2.843, t-test p < 0.001).
This table shows molecular features associated with FAM99B in patient tissues and cancer cell lines. In patient samples, FAM99B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
